These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 9551618)
1. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Pützer BM; Bramson JL; Addison CL; Hitt M; Siegel PM; Muller WJ; Graham FL Hum Gene Ther; 1998 Mar; 9(5):707-18. PubMed ID: 9551618 [TBL] [Abstract][Full Text] [Related]
2. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Addison CL; Bramson JL; Hitt MM; Muller WJ; Gauldie J; Graham FL Gene Ther; 1998 Oct; 5(10):1400-9. PubMed ID: 9930346 [TBL] [Abstract][Full Text] [Related]
3. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model. Emtage PC; Wan Y; Bramson JL; Graham FL; Gauldie J J Immunol; 1998 Mar; 160(5):2531-8. PubMed ID: 9498799 [TBL] [Abstract][Full Text] [Related]
4. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Emtage PC; Wan Y; Hitt M; Graham FL; Muller WJ; Zlotnik A; Gauldie J Hum Gene Ther; 1999 Mar; 10(5):697-709. PubMed ID: 10210138 [TBL] [Abstract][Full Text] [Related]
5. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Pützer BM; Hitt M; Muller WJ; Emtage P; Gauldie J; Graham FL Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10889-94. PubMed ID: 9380730 [TBL] [Abstract][Full Text] [Related]
6. Enhanced interleukin-2 gene transfer immunotherapy of breast cancer by coexpression of B7-1 and B7-2. Emtage PC; Wan Y; Muller W; Graham FL; Gauldie J J Interferon Cytokine Res; 1998 Nov; 18(11):927-37. PubMed ID: 9858314 [TBL] [Abstract][Full Text] [Related]
7. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Addison CL; Braciak T; Ralston R; Muller WJ; Gauldie J; Graham FL Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8522-6. PubMed ID: 7667323 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity. Slos P; De Meyer M; Leroy P; Rousseau C; Acres B Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452 [TBL] [Abstract][Full Text] [Related]
9. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models. Nielsen LL; Gurnani M; Syed J; Dell J; Hartman B; Cartwright M; Johnson RC Hum Gene Ther; 1998 Mar; 9(5):681-94. PubMed ID: 9551616 [TBL] [Abstract][Full Text] [Related]
10. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Ahn WS; Bae SM; Kim TY; Kim TG; Lee JM; Namkoong SE; Kim CK; Sin JI Hum Gene Ther; 2003 Oct; 14(15):1389-99. PubMed ID: 14577920 [TBL] [Abstract][Full Text] [Related]
11. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Bramson JL; Hitt M; Gauldie J; Graham FL Gene Ther; 1997 Oct; 4(10):1069-76. PubMed ID: 9415313 [TBL] [Abstract][Full Text] [Related]
12. p53 gene transfer does not enhance E2F-1-mediated apoptosis in human colon cancer cells. Draus JM; Elliott MJ; Atienza C; Stilwell A; Wong SL; Dong Y; Yang H; McMasters KM Exp Mol Med; 2001 Dec; 33(4):209-19. PubMed ID: 11795482 [TBL] [Abstract][Full Text] [Related]
13. Genetic immunotherapy for medullary thyroid carcinoma: destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene. Zhang R; Baunoch D; DeGroot LJ Thyroid; 1998 Dec; 8(12):1137-46. PubMed ID: 9920370 [TBL] [Abstract][Full Text] [Related]
15. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154. Loskog A; Tötterman TH; Böhle A; Brandau S Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026 [TBL] [Abstract][Full Text] [Related]
16. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12. Gambotto A; Tüting T; McVey DL; Kovesdi I; Tahara H; Lotze MT; Robbins PD Cancer Gene Ther; 1999; 6(1):45-53. PubMed ID: 10078963 [TBL] [Abstract][Full Text] [Related]
17. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Toloza EM; Hunt K; Swisher S; McBride W; Lau R; Pang S; Rhoades K; Drake T; Belldegrun A; Glaspy J; Economou JS Cancer Gene Ther; 1996; 3(1):11-7. PubMed ID: 8785705 [TBL] [Abstract][Full Text] [Related]
18. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy. Gyorffy S; Palmer K; Podor TJ; Hitt M; Gauldie J J Immunol; 2001 May; 166(10):6212-7. PubMed ID: 11342643 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Nielsen LL; Dell J; Maxwell E; Armstrong L; Maneval D; Catino JJ Cancer Gene Ther; 1997; 4(2):129-38. PubMed ID: 9080122 [TBL] [Abstract][Full Text] [Related]
20. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma. Hillman GG; Slos P; Wang Y; Wright JL; Layer A; De Meyer M; Yudelev M; Che M; Forman JD Cancer Gene Ther; 2004 Jan; 11(1):61-72. PubMed ID: 14681727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]